Fulminant colitis from Clostridium difficile infection, the epidemic strain ribotype 027, in Japan

Journal of Infection and Chemotherapy

Volumn 20, Issue 6, 2014, Pages 380-383

  Nakamura, Itaru ^a   Yamaguchi, Tetsuo ^a,b   Tsukimori, Ayaka ^a   Sato, Akihiro ^a   Fukushima, Shinji ^a   Mizuno, Yasutaka ^a   Matsumoto, Tetsuya ^a,b  

^a TOKYO MEDICAL UNIVERSITY HOSPITAL   (Japan)

^b TOKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Clostridium difficile; Epidemic strain; Fulminant colitis; Ribotype 027

Indexed keywords

C REACTIVE PROTEIN; CEFAZOLIN; CEFOZOPRAN; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; IMMUNOGLOBULIN; ISEPAMICIN; LINEZOLID; METRONIDAZOLE; MICAFUNGIN; MOXIFLOXACIN; QUINOLONE DERIVATIVE; SERUM ALBUMIN; SULTAMICILLIN; VANCOMYCIN; ANTIINFECTIVE AGENT;

ABDOMINAL PAIN; ABDOMINAL WALL; ADULT; ALBUMIN BLOOD LEVEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM CULTURE; BODY TEMPERATURE; CASE REPORT; CESAREAN SECTION; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; COLITIS; COLON RESECTION; COLOSTOMY; COMPUTER ASSISTED TOMOGRAPHY; DIARRHEA; DISEASE CONTROL; DNA SEQUENCE; EMERGENCY SURGERY; ENTERAL DRUG ADMINISTRATION; ENTEROCOCCUS FAECALIS; EPIDEMIC; FEMALE; FEVER; FULMINANT COLITIS; GENE DELETION; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; ILEUS; INTESTINE PERFORATION; JAPAN; LEUKOCYTE COUNT; LOOSE FECES; PARALYTIC ILEUS; PERITONEAL FLUID; PERITONITIS; PHARMACIST; POLYMERASE CHAIN REACTION; RAPID TEST; RIBOTYPING; TREATMENT RESPONSE; UNIVERSITY HOSPITAL; CLASSIFICATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; GENETICS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ADULT; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; COLOSTOMY; ENTEROCOLITIS, PSEUDOMEMBRANOUS; EPIDEMICS; FEMALE; HUMANS; JAPAN; RIBOTYPING;

EID: 84903593796     PISSN: 1341321X     EISSN: 14377780     Source Type: Journal    
DOI: 10.1016/j.jiac.2013.11.009     Document Type: Article

References (21)

1. Kato H, Ito Y, van den Berg RJ, Kuijper EJ, Arakawa Y. First isolation of Clostridium difficile 027 in Japan. Euro Surveill 2007;12. E070111 3.
2. McDonald LC, Killgore GE, Thompson A, Owens Jr RC, Kazakova SV, Sambol SP, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353: 2433-41.
3. Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficileassociated diarrhea with high morbidity and mortality. N Engl J Med 2005;353: 2442-9.
4. Sawabe E, Kato H, Osawa K, Chida T, Tojo N, Arakawa Y, et al. Molecular analysis of Clostridium difficile at a university teaching hospital in Japan: a shift in the predominant type over a five-year period. Eur J Clin Microbiol Infect Dis 2007;26: 695-703.
5. Lemee L, Dhalluin A, Testelin S, Mattrat MA, Maillard K, Lemeland JF, et al. Multiplex PCR targeting tpi (triose phosphate isomerase), tcdA (Toxin A), and tcdB (Toxin B) genes for toxigenic culture of Clostridium difficile. J Clin Microbiol 2004;42: 5710-4.
6. Bidet P, Barbut F, Lalande V, Burghoffer B, Petit JC. Development of a new PCRribotyping method for Clostridium difficile based on ribosomal RNA gene sequencing. FEMS Microbiol Lett 1999;175: 261-6.
7. Wong SS, Woo PC, Luk WK, Yuen KY. Susceptibility testing of Clostridium difficile against metronidazole and vancomycin by disk diffusion and Etest. Diagn Microbiol Infect Dis 1999;34: 1-6.
8. Muto CA, Pokrywka M, Shutt K, Mendelsohn AB, Nouri K, Posey K, et al. A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use. Infect Control Hosp Epidemiol 2005;26:273-80.
9. Tagashira Y, Kato H, Senoh M, Nakamura A. Two cases of fulminant colitis due to binary toxin-positive Clostridium difficile, that are not Pcr ribotype 027 nor type 078. J Med Microbiol 2013.
10. Goorhuis A, Bakker D, Corver J, Debast SB, Harmanus C, Notermans DW, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008;47: 1162-70.
11. Iwashima Y, Nakamura A, Kato H, Wakimoto Y, Wakiyama N, Kaji C, et al. A retrospective study of the epidemiology of Clostridium difficile infection at a University Hospital in Japan: genotypic features of the isolates and clinical characteristics of the patients. J Infect Chemother 2010;16: 329-33.
12. Cohen SH, Gerding DN, Johnson S, Kelly CP, Loo VG, McDonald LC, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010;31: 431-55.
13. Akerlund T, Svenungsson B, Lagergren A, Burman LG. Correlation of disease severity with fecal toxin levels in patients with Clostridium difficile-associated diarrhea and distribution of PCR ribotypes and toxin yields in vitro of corresponding isolates. J Clin Microbiol 2006;44: 353-8.
14. Riegler M, Sedivy R, Pothoulakis C, Hamilton G, Zacherl J, Bischof G, et al. Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest 1995;95: 2004-11.
15. McEllistrem MC, Carman RJ, Gerding DN, Genheimer CW, Zheng L. A hospital outbreak of Clostridium difficile disease associated with isolates carrying binary toxin genes. Clin Infect Dis 2005;40: 265-72.
16. Neal MD, Alverdy JC, Hall DE, Simmons RL, Zuckerbraun BS. Diverting loop ileostomy and colonic lavage: an alternative to total abdominal colectomy for the treatment of severe, complicated Clostridium difficile associated disease. Ann Surg 2011;254:423-7 [discussion 7-9].
17. Valerio M, Pedromingo M, Munoz P, Alcala L, Marin M, Pelaez T, et al. Potential protective role of linezolid against Clostridium difficile infection. Int J Antimicrob Agents 2012;39: 414-9.
18. Baines SD, Noel AR, Huscroft GS, Todhunter SL, O'Connor R, Hobbs JK, et al. Evaluation of linezolid for the treatment of Clostridium difficile infection caused by epidemic strains using an in vitro human gut model. J Antimicrob Chemother 2011;66: 1537-46.
19. Ackermann G, Adler D, Rodloff AC. In vitro activity of linezolid against Clostridium difficile. J Antimicrob Chemother 2003;51: 743-5.
20. Zabel LT, Worm S. Linezolid contributed to Clostridium difficile colitis with fatal outcome. Infection 2005;33: 155-7.
21. Rubinstein E, Isturiz R, Standiford HC, Smith LG, Oliphant TH, Cammarata S, et al. Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003;47: 1824-31.